About This Fund
Atlas Venture Fund XIV is the fourteenth flagship early-stage venture capital fund of Atlas Venture, one of the most prolific and respected biotech-focused venture capital firms in the United States. Founded in Cambridge, Massachusetts, Atlas Venture has specialized in creating and co-founding breakthrough biotechnology companies since the early 1990s, earning a reputation for its founder-centric, seed-led venture creation model and its deep scientific and clinical expertise. The firm operates primarily within the Cambridge and Boston life sciences ecosystem, which is home to some of the world's leading academic medical centers, pharmaceutical companies, and biotechnology clusters.
Atlas Venture Fund XIV continues the firm's disciplined, focused investment strategy of partnering with exceptional scientists and entrepreneurs to found, seed, incubate, and invest in new biotechnology startups developing transformative medicines. The fund targets seed and early Series A-stage investments in companies applying novel biological insights to address significant unmet medical needs across drug discovery, cell and gene therapy, clinical-stage biopharmaceuticals, and medical innovation. Atlas typically leads or co-leads its initial investments and maintains active involvement through establishment of management teams, scientific advisory boards, and early clinical development programs. The investing partners in Fund XIV are Kevin Bitterman, Bruce Booth, Michael Gladstone, David Grayzel, and Jason Rhodes.
Atlas Venture Fund XIV closed at USD 450 million on December 5, 2024, in an oversubscribed process that the firm's partners described as the smoothest, most efficient, and most oversubscribed fundraise in the firm's twenty-year history. The close followed a strong period for predecessor Atlas Venture Fund XIII (closed 2022), during which portfolio companies including Nimbus Therapeutics' Tyk2 program, Versanis Bio, Aiolos Bio, and Mariana Oncology were acquired by pharmaceutical partners, while Disc Medicine, Korro Bio, Q32 Bio, and Third Harmonic Bio became publicly traded companies. Atlas has launched sixteen new biotechnology companies in the two years following Fund XIII's close.